Adjusted for cell proportions: TRUE **IFX** ADA IFX - ADA pooled enriched in B cells (I) (LI.M47.0) enriched in B cells (II) (LI.M47.1) enriched in T cells (I) (LI.M7.0) -B cell surface signature (LI.S2) plasma cells & B cells, immunoglobulins (LI.M156.0) -T cell activation (I) (LI.M7.1) enriched in NK cells (I) (LI.M7.2) enriched in B cells (III) (LI.M47.2) enriched in B cells (VI) (LI.M69) plasma cells, immunoglobulins (LI.M156.1) -T cell activation (II) (LI.M7.3) -T cell surface signature (LI.S0) -T cell differentiation (Th2) (LI.M19) -T cell activation and signaling (LI.M5.1) -Gene module myeloid, dendritic cell activation via NFkB (I) (LI.M43.0) platelet activation & blood coagulation (LI.M199) myeloid, dendritic cell activation via NFkB (II) (LI.M43.1) platelet activation – actin binding (LI.M196) cell adhesion (LI.M51) enriched in activated dendritic cells/monocytes (LI.M64) blood coagulation (LI.M11.1) -TBA (LI.M55) cell cycle and transcription (LI.M4.0) enriched in myeloid cells and monocytes (LI.M81) enriched in monocytes (IV) (LI.M118.0) -Monocyte surface signature (LI.S4) enriched in neutrophils (I) (LI.M37.1) -TLR and inflammatory signaling (LI.M16) enriched in monocytes (II) (LI.M11.0) immune activation - generic cluster (LI.M37.0) --log10(FDR)

Direction of effect

Up in PR

Effect size (AUC)

0.6

Down in PR

Not significant